BPC-157 and nerve tissue: what the rodent studies examined

Prepared by: Research Desk. Sources are linked for verification.

Status: Not approved. BPC-157 is not FDA-approved for any use and is prohibited in sport under the WADA code. See our legal status file for the dated record.

Online searches for "BPC-157 nerve" turn up confident claims about nerves, the spinal cord and the brain. The published record behind those claims is much narrower. It consists of a small number of rat and mouse experiments and a set of narrative reviews, and almost all of it comes from the research group in Croatia that first described the peptide. None of the sources we track report a controlled human study of nerve or brain outcomes.

This file sets out, study by study, which species was used, which injury model, what was measured and who did the work. It does not read any of these findings as evidence about people.

How to read this file

Each entry below answers four questions: what animal, what model, what outcomes, and what the limits are. For the wider picture of how rodent models are used across the BPC-157 literature, see our overview of BPC-157 animal studies. For the biological pathways the same group has proposed, see BPC-157 mechanism. Tendon and gut experiments are covered in separate files and are not repeated here.

We do not list group sizes or administration details. The abstracts and reviews we cite do not let us verify group sizes consistently, and this site does not publish dosing or route information. Anyone checking a specific number should go to the full paper.

Peripheral nerve: the rat sciatic nerve transection study

Source: Gjurasin and colleagues, Regulatory Peptides, 2010 [1].

• Species: rats.

• Model: the sciatic nerve was cut through (transection). In some animals the cut ends were rejoined surgically (anastomosis). In others a nerve-tube approach was used to bridge the gap.

• What was measured: autotomy, a self-injury behaviour rats show after nerve damage; microscopic and morphometric measures of nerve tissue, including axon and myelin features; electromyography (EMG), including motor action potentials; and walking function scored with the sciatic functional index.

• What was reported: the authors reported more favourable values in BPC-157 groups than in controls across the structural, electrophysiological and walking measures [1].

Limits. This is one study, from the research network that produced most of the BPC-157 literature, and we have not found independent replication in our source list. Its outcomes are laboratory measures of nerve structure and rat gait in a controlled surgical model. They cannot show what would happen after nerve injury in a person.

Spinal cord: rat compression injury

Source: Perovic and colleagues, Current Issues in Molecular Biology, 2022 [2].

• Species: rats.

• Model: a compression injury of the lower spinal cord, assessed through tail function. The paper looked at both early injury and established ("definitive") injury, meaning administration began at different times after the injury was made.

• What was measured: tail motor function and spasticity; tissue findings such as edema, vacuolation, loss of axons and neurons, demyelination and cyst formation; EMG recordings; and changes in gene expression.

• What was reported: the authors reported more favourable functional, tissue and EMG findings in BPC-157 groups than in controls, in both the early and the established injury settings [2]. The word "recovery" in the paper's title is the authors' description of these rat outcomes.

Limits. A tail-function model of lower spinal cord compression is a long way from the range of human spinal cord injuries. The work again comes from the originating group. Gene-expression changes and tissue scores are intermediate measures, not functional outcomes in people.

Brain and neurotransmitter work

The brain literature is broader and more scattered. Most of it reaches readers through reviews written by the same group.

• Central nervous system review. Vukojevic and colleagues (Neural Regeneration Research, 2022) summarise animal studies covering brain injury and edema measures, behaviour and neurological scores, and experimentally induced disturbances of dopamine and serotonin systems. They also discuss other neurotransmitter systems [3]. These are separate experiments with different models, not a single coordinated programme.

• Brain-gut axis reviews. Two reviews from Sikiric and colleagues set out a theoretical framework linking the peptide's gut findings to brain function. One appeared in 2016 [4] and a follow-up appeared in 2023 [5]. Both are interpretive reviews of the group's own work, not systematic reviews with independent appraisal of study quality.

• Ethanol in mice. Blagaic and colleagues (European Journal of Pharmacology, 2004) examined the influence of BPC-157 in mice given ethanol acutely and chronically [6]. It is one of the few mouse studies in this area and sits at the edge of the nerve literature rather than at its centre.

Limits. The outcomes in this cluster are mostly behavioural scores, tissue measures and neurotransmitter-related changes induced by drugs or injury in rodents. A narrative review that collects one laboratory's positive findings cannot tell us how often results were replicated elsewhere, or how many neutral results went unpublished.

Summary table

Common threads and gaps

Three patterns run through this material.

1. One research network. Every entry above involves the originating group or close collaborators. Independent replication is the missing piece, and it matters more than any single positive result.

2. Reviews quoting reviews. Much of the CNS picture reaches readers through narrative reviews by the same authors. These are useful maps of what was done. They are not neutral audits of it.

3. Surrogate outcomes. Nerve morphometry, EMG traces, tail scores and neurotransmitter measures are reasonable laboratory endpoints. They are not the same as function, symptoms or safety in people.

Our checklist on how to evaluate a BPC-157 study walks through how to spot these issues in any paper.

What the human literature covers, and what it doesn't

A 2026 systematic review set out to collect the human evidence for BPC-157 in orthopaedic and regenerative medicine, covering both efficacy and safety [7]. The small human reports in our source list do not concern nerves. One is a report on several types of knee pain [8]. The other is a pilot study of intravenous safety [9]. A 2025 systematic review in orthopaedic sports medicine notes that BPC-157 lacks FDA approval and is banned in professional sport, even as use by athletes grows [10].

We have found no human trial of nerve, spinal cord or brain outcomes in our sources. Our evidence guide sets the animal and human records side by side.

Regulatory context in brief

FDA lists BPC-157 among bulk drug substances that may present significant safety risks in compounding. Its entry records concerns about immunogenicity and notes that the nominations were withdrawn [11]. FDA's Pharmacy Compounding Advisory Committee also met on 23–24 July 2026 [12]. WADA's Prohibited List applies in sport [13]. The full dated record, including how BPC-157 figures in that committee meeting, is in our legal status file.

Further reading: books on judging research

The studies above show why the skill of reading a paper matters as much as the paper itself. A good methods book will train that skill across any field. When comparing titles, these neutral criteria are worth checking:

• Coverage of animal and laboratory research: does the book explain blinding, randomisation and publication bias in preclinical work, or only in human trials?

• Statistics level: introductory books suit general readers, while books that cover effect sizes and confidence intervals suit readers going deeper.

• Edition date: methods teaching changes, so a recent edition is usually better than an old classic.

• Worked examples: books that dissect real published papers transfer better than abstract theory.

• Format and price: tables and figures read poorly as audio. Used copies of earlier editions can cut costs if the core chapters are unchanged.

• Author background: look for authors with a track record in research methods, statistics or evidence synthesis.

We choose titles only on the criteria above. See how this site handles disclosures and affiliate links.

A short, well-written statistics primer often does more for critical reading than a long specialist textbook.

Frequently asked questions

Has BPC-157 been tested on nerve injuries in humans?

Not in any controlled study in our sources. The human reports we track concern knee pain and an intravenous safety pilot, and neither measured nerve or brain outcomes [8][9].

Which animals were used in the BPC-157 nerve studies?

Mainly rats, in the sciatic nerve and spinal cord experiments [1][2]. One study used mice, in an ethanol model [6]. The brain findings are summarised in reviews of rodent work [3].

Why does it matter that one group produced most of the BPC-157 nerve research?

A finding carries more weight once unrelated laboratories have reproduced it. Without that replication, unnoticed problems in methods, analysis or selective publication are harder to rule out.

Does the rat spinal cord study say anything about people with spinal cord injury?

No. It measured tail function, tissue changes and gene expression after a specific compression injury in rats [2]. Those results cannot establish effects or safety in humans.

Related on this site

• BPC-157: the evidence file

• BPC-157 animal studies: what rodent models can and cannot show

• BPC-157 mechanism: the pathways proposed in lab studies

• BPC-157 history: where the gastric peptide research came from

• BPC-157: what the evidence actually shows (and doesn't)

• Is BPC-157 legal? FDA, compounding and anti-doping status

Last updated: 21 October 2026.

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.